Identification of seven tumor-educated platelets RNAs for cancer diagnosis.
Biomarkers, Tumor
/ blood
Blood Platelets
/ metabolism
Case-Control Studies
Cell Cycle Proteins
/ genetics
Computational Biology
/ methods
GTP-Binding Proteins
/ genetics
Gene Expression Profiling
Gene Regulatory Networks
Humans
Neoplasm Metastasis
Neoplasms
/ blood
Prognosis
RNA, Neoplasm
/ blood
Receptors, IgG
/ genetics
Transcriptome
bioinformatics analysis
diagnosis
mRNA
tumor educated platelets
Journal
Journal of clinical laboratory analysis
ISSN: 1098-2825
Titre abrégé: J Clin Lab Anal
Pays: United States
ID NLM: 8801384
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
25
03
2021
accepted:
01
04
2021
pubmed:
7
5
2021
medline:
15
12
2021
entrez:
6
5
2021
Statut:
ppublish
Résumé
Tumor-educated platelets (TEPs) may enable blood-based cancer diagnosis. This study aimed to identify diagnostic TEPs genes involved in carcinogenesis. The TEPs differentially expressed genes (DEGs) between healthy samples and early/advanced cancer samples were obtained using bioinformatics. Gene ontology (GO) analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were used to identify the pathways and functional annotation of TEPs DEGs. Protein-protein interaction of these TEPs DEGs was analyzed based on the STRING database and visualized by Cytoscape software. The correlation analysis and diagnostic analysis were performed to evaluate the diagnostic value of TEPs mRNAs expression for early/advanced cancers. Quantitative real-time PCR (qRT-PCR) was applied to validate the role of DEGs in cancers. TEPs mRNAs were mostly involved in protein binding, extracellular matrix, and cellular protein metabolic process. RSL24D1 was negatively correlated to early-stage cancers compared to healthy controls and may be potentially used for early cancer diagnosis. In addition, HPSE, IFI27, LGALS3BP, CRYM, HBD, COL6A3, LAMB2, and IFITM3 showed an upward trend in the expression from early to advanced cancer stages. Moreover, ARL2, FCGR2A, and KLHDC8B were positively associated with advanced, metastatic cancers compared to healthy controls. Among the 12 selected DEGs, the expression of 7 DEGs, including RSL24D1, IFI27, CRYM, HBD, IFITM3, FCGR2A, and KLHDC8B, were verified by the qRT-PCR method. This study suggests that the 7-gene TEPs liquid-biopsy biomarkers may be used for cancer diagnosis and monitoring.
Sections du résumé
BACKGROUND
BACKGROUND
Tumor-educated platelets (TEPs) may enable blood-based cancer diagnosis. This study aimed to identify diagnostic TEPs genes involved in carcinogenesis.
MATERIALS AND METHODS
METHODS
The TEPs differentially expressed genes (DEGs) between healthy samples and early/advanced cancer samples were obtained using bioinformatics. Gene ontology (GO) analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were used to identify the pathways and functional annotation of TEPs DEGs. Protein-protein interaction of these TEPs DEGs was analyzed based on the STRING database and visualized by Cytoscape software. The correlation analysis and diagnostic analysis were performed to evaluate the diagnostic value of TEPs mRNAs expression for early/advanced cancers. Quantitative real-time PCR (qRT-PCR) was applied to validate the role of DEGs in cancers.
RESULTS
RESULTS
TEPs mRNAs were mostly involved in protein binding, extracellular matrix, and cellular protein metabolic process. RSL24D1 was negatively correlated to early-stage cancers compared to healthy controls and may be potentially used for early cancer diagnosis. In addition, HPSE, IFI27, LGALS3BP, CRYM, HBD, COL6A3, LAMB2, and IFITM3 showed an upward trend in the expression from early to advanced cancer stages. Moreover, ARL2, FCGR2A, and KLHDC8B were positively associated with advanced, metastatic cancers compared to healthy controls. Among the 12 selected DEGs, the expression of 7 DEGs, including RSL24D1, IFI27, CRYM, HBD, IFITM3, FCGR2A, and KLHDC8B, were verified by the qRT-PCR method.
CONCLUSION
CONCLUSIONS
This study suggests that the 7-gene TEPs liquid-biopsy biomarkers may be used for cancer diagnosis and monitoring.
Identifiants
pubmed: 33955587
doi: 10.1002/jcla.23791
pmc: PMC8183939
doi:
Substances chimiques
Biomarkers, Tumor
0
Cell Cycle Proteins
0
FCGR2A protein, human
0
KLHDC8B protein, human
0
RNA, Neoplasm
0
Receptors, IgG
0
ARL2 protein, human
EC 3.6.1.-
GTP-Binding Proteins
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23791Subventions
Organisme : National Natural Science Foundation of China
ID : 81130008
Informations de copyright
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
Références
Ann Oncol. 2018 Nov 1;29(11):2232-2239
pubmed: 30203045
Int J Biol Sci. 2019 Jul 24;15(9):1977-1992
pubmed: 31523198
FEBS Open Bio. 2018 Jun 28;8(8):1299-1311
pubmed: 30087833
Onco Targets Ther. 2018 Nov 14;11:8143-8151
pubmed: 30532555
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
J Cancer Res Clin Oncol. 2019 Nov;145(11):2713-2723
pubmed: 31552488
Cancer Res. 2020 Apr 1;80(7):1371-1373
pubmed: 32075797
Cancer Cell. 2017 Aug 14;32(2):238-252.e9
pubmed: 28810146
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Syst. 2019 Aug 28;9(2):109-127
pubmed: 31465728
Pharmacogenomics J. 2018 May 22;18(3):474-479
pubmed: 28719596
J Hematol Oncol. 2018 Oct 11;11(1):125
pubmed: 30305116
J Virol. 2016 Jul 11;90(15):6832-45
pubmed: 27194766
World J Surg Oncol. 2018 Mar 27;16(1):64
pubmed: 29580248
Cancer Res. 2018 Jul 1;78(13):3407-3412
pubmed: 29921699
BMC Infect Dis. 2012 Dec 28;12:384
pubmed: 23272999
Sci Rep. 2018 Apr 26;8(1):6564
pubmed: 29700384
Nat Biotechnol. 2014 May;32(5):441-3
pubmed: 24811515
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Clin Res Hepatol Gastroenterol. 2020 Nov;44(6):836-844
pubmed: 32312598
Breast Cancer. 2018 Mar;25(2):198-205
pubmed: 29101635
PLoS One. 2009 Oct 15;4(10):e7478
pubmed: 19829707
J Glob Health. 2019 Dec;9(2):020411
pubmed: 31360449
Ann Oncol. 2016 Apr;27(4):635-41
pubmed: 26681674
Oncol Res Treat. 2017;40(7-8):404-408
pubmed: 28693023
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W169-75
pubmed: 17576678
Pharmacol Ther. 2016 Jan;157:112-9
pubmed: 26615781
Aging (Albany NY). 2019 Oct 22;11(20):8998-9012
pubmed: 31639773
Biol Cell. 2017 Feb;109(2):94-112
pubmed: 27673746
Eur J Hum Genet. 2018 Jul;26(7):937-945
pubmed: 29681621
Mol Oncol. 2021 Jun;15(6):1727-1743
pubmed: 33219615
PLoS One. 2009 Oct 08;4(10):e7385
pubmed: 19812699
Cell Death Dis. 2019 Jul 4;10(7):517
pubmed: 31273201
Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361
pubmed: 27899662
Nat Rev Clin Oncol. 2014 Mar;11(3):129-44
pubmed: 24445517
Cancer Res. 2020 Jan 15;80(2):291-303
pubmed: 31727628
Apoptosis. 2008 Apr;13(4):562-72
pubmed: 18330707
Blood. 2011 Sep 29;118(13):3680-3
pubmed: 21832279
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819837261
pubmed: 30871415
Cell Commun Signal. 2019 Nov 7;17(1):142
pubmed: 31699102
Cancer Gene Ther. 2020 Feb;27(1-2):38-44
pubmed: 30923336
Oncotarget. 2014 Jul 15;5(13):4959-71
pubmed: 24970806
Cancer Cell. 2015 Nov 9;28(5):666-676
pubmed: 26525104
J Comput Biol. 2020 Nov;27(11):1595-1609
pubmed: 32216644
Oncol Lett. 2019 Jul;18(1):571-580
pubmed: 31289529
Blood. 2018 Apr 19;131(16):1777-1789
pubmed: 29519806
J Clin Med. 2019 Aug 25;8(9):
pubmed: 31450665
Lancet. 2000 Apr 29;355(9214):1531-9
pubmed: 10801186
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Lab Chip. 2018 Dec 18;19(1):11-34
pubmed: 30480287
Eur Rev Med Pharmacol Sci. 2015 Nov;19(21):4139-45
pubmed: 26592840
Nephrol Dial Transplant. 2016 Feb;31(2):262-9
pubmed: 26420894
Biochem Soc Trans. 2018 Dec 17;46(6):1517-1527
pubmed: 30420412
Virus Res. 2017 Jan 2;227:231-239
pubmed: 27777077